Our patents
Cantargia's strategy is to obtain an extensive patent protection for its current and future product candidates. Cantargia has patent protection for the treatment of a large number of different cancer forms using antibodies directed against IL1RAP. Cantargia also has a patent family covering the product candidate nadunolimab (CAN04), as well as several patent families covering other antibodies targeting IL1RAP. Cantargia's patent strategy is global, and covers markets deemed to be of clinical and commercial relevance for the product pipeline. During 2025, Cantargia’s patent covering the CAN10 antibody was acquired by Otsuka Pharmaceutical.
CANTARGIA’S PROPRIETARY PROJECT PORTFOLIO
The expiry dates shown below exclude potential Supplementary Protection Certificates (SPC) and Patent Term Extensions (PTE) and/or potential regulatory data exclusivity periods.
| Patent family | Patent application | Approved patents | Validity |
|---|---|---|---|
| Nadunolimab (Product) | USA | Australia, Brazil, Canada, China, Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, UK), India, Israel, Japan, Mexico, Singapore, South Africa, South Korea, USA | 2035 |
| Leukemias (Treatment) | USA | 2029 | |
| Hematological cancers (Treatment/Diagnosis) | China | Australia, Brazil, Canada, China, Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, UK), India, Israel, Japan, Mexico, Singapore, South Africa, South Korea, USA | 2030 |
| Solid tumors (Treatment/Diagnosis) | China, Europe | Australia, Brazil, Canada, Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, UK), Japan, Mexico, South Korea, USA | 2032 |
| CAN03 (Product) | China, Europe (France, Germany, UK), Japan, USA | 2035 | |
| Anti-IL1RAP antibodies (Product) | Europe | China, Japan, USA | 2037 |
| Biepitopic antibody (Product) | USA | Europe (France, Germany, UK) | 2039 |
STRATEGIC PARTNERSHIPS
The expiry dates shown below exclude potential Supplementary Protection Certificates (SPC) and Patent Term Extensions (PTE) and/or potential regulatory data exclusivity periods. The patent families listed below are owned by Otsuka Pharmaceutical since 2025.
| Patent family | Patent application | Approved patents | Validity |
|---|---|---|---|
| CAN10 (Product) | Australia, Brazil, Canada, China, Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, UK), India, Israel, Japan, Mexico, Singapore, South Africa, South Korea | USA | 2041 |
| 3G5 (Product) | PCT, Australia, Canada, China, New Zeeland, India, Israel, Indonesia, Singapore, South Africa, South Korea | 2044 |
